{"preliminary_commentary":{"by_channel":{"x_thread":7,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04923906\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"AENEAS2","nct_id":"NCT04923906","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=aeneas2-nct04923906. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Aumolertinib and platinum-based chemotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Aumolertinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-01-31","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":624,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Aumolertinib","otherNames":["HS-10296"],"type":"DRUG"},{"name":"Placebo Aumolertinib","otherNames":[],"type":"DRUG"}],"last_update":"2024-11-25","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","official_title":"Efficacy and Safety of Aumolertinib with or Without Chemotherapy As First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing Epidermal Growth Factor Receptor Mutations: a Randomized, Controlled, Open-label, Phase 3 and Multicenter Clinical Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-06-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS (Progression Free Survival) assessed by IRC (Independent Review Committee)","timeFrame":"From the time of randomization to disease progression or death, approximately 3 years."}],"references":[{"citation":"Li Z, Hu J, Chen J, Yu Y, Meng X, Dong X, Hu Y, Ji Y, Liu H, Wang W, Ning F, Zhang Z, Liu C, Zhang Z, Wang Q, Zheng W, Wang H, Qu X, Chen Z, Fan S, Zhang X, Lu S. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2026 Jul;27(7):785-794. doi: 10.1016/S1470-2045(26)00090-2. Epub 2026 Jun 15.","pmid":"42296979","type":"DERIVED"}],"start_date":{"date":"2021-08-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations","url":"https://clinicaltrials.gov/study/NCT04923906"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/aeneas2-nct04923906"}